First Clinical Study of a RSVpreF Vaccine in Healthy Volunteers

First Clinical Study of a RSVpreF Vaccine in Healthy Volunteers. A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding, First-in-Human Study to Describe the Safety, Tolerability, and Immunogenicity of A Respiratory Syncytial Virus (RSV) Vaccine in Healthy Adults.

Category & Conditions:
Vaccine-related Conditions
Medicine:
PF-06928316
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
C3671001
Open Plain Language Summary Result:Click here